SEARCH RESULTS FOR: ("Make Dominican School of Philosophy")(70002 results)
Only the first 10,000 results were returned. Filter these results or refine your query. Some pre-built queries with more than 10,000 results are available for download.
Automated External Defibrillator
HEARTSINE TECHNOLOGIES LTD
SAM360P
In Commercial Distribution
- 05060167120718 ()
360-STR-US-AV
- Non-rechargeable public automated external defibrillator
Automated External Defibrillator
HEARTSINE TECHNOLOGIES LTD
SAM 350P
In Commercial Distribution
- 05060167120701 ()
350-STR-US-AV
- Non-rechargeable public semi-automated external defibrillator
Automated External Defibrillator
HEARTSINE TECHNOLOGIES LTD
SAM450P
In Commercial Distribution
- 05060167120695 ()
450-STR-US-10
- Non-rechargeable public semi-automated external defibrillator
Automated External Defibrillator
HEARTSINE TECHNOLOGIES LTD
SAM 360P
In Commercial Distribution
- 05060167120688 ()
360-STR-US-10
- Non-rechargeable public automated external defibrillator
Automated External Defibrillator
HEARTSINE TECHNOLOGIES LTD
SAM 350P
In Commercial Distribution
- 05060167120671 ()
350-STR-US-10
- Non-rechargeable public semi-automated external defibrillator
The therascreen FGFR RGQ RT-PCR Kit is a real-time, reverse transcription PCR test for the qualitative detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3) in the fibroblast growth factor receptor 3 (FGFR3) gene in RNA samples derived from formalin-fixed paraffin-embedded (FFPE) urothelial tumor tissue. The test is indicated for use as an aid in identifying patients with cases of urothelial cancer (UC) which harbor these alterations and are therefore eligible for treatment with BALVERSA™ (erdafitinib).
Specimens are processed using the RNeasy DSP FFPE Kit for manual sample preparation followed by reverse transcription and then automated amplification and detection on the Rotor-Gene Q MDx (US) instrument.
QIAGEN GmbH
2
In Commercial Distribution
- 04053228043560 ()
874721
- Fibroblast growth factor receptor (FGFR) gene mutation IVD, kit, nucleic acid technique (NAT)
The DETOUR System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature
PQ Bypass, Inc.
TSG-6.7X200
In Commercial Distribution
- 00860008946478 ()
- 6.7mm Stent Graft Proximal Diameter
- 6.7mm Stent Graft Distal Diameter
- 135cm Catheter Working Length
- 8F Delivery System Outer Profile
- 200mm Covered Stent Graft Length
TSG-6.7X200
- Central/peripheral venous endovascular stent-graft
The DETOUR System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature
PQ Bypass, Inc.
TSG-6.7X150
In Commercial Distribution
- 00860008946461 ()
- 6.7mm Stent Graft Proximal Diameter
- 6.7mm Stent Graft Distal Diameter
- 135cm Catheter Working Length
- 8F Delivery System Outer Profile
- 150mm Covered Stent Graft Length
TSG-6.7X150
- Central/peripheral venous endovascular stent-graft
The DETOUR System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature
PQ Bypass, Inc.
TSG-6.7X100
In Commercial Distribution
- 00860008946454 ()
- 6.7mm Stent Graft Proximal Diameter
- 6.7mm Stent Graft Distal Diameter
- 135cm Catheter Working Length
- 8F Delivery System Outer Profile
- 100mm Covered Stent Graft Length
TSG-6.7X100
- Central/peripheral venous endovascular stent-graft
The DETOUR System is indicated for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature
PQ Bypass, Inc.
TSG-6.0X200
In Commercial Distribution
- 00860008946447 ()
- 6.0 mm Stent Graft Proximal Diameter
- 6.0 mm Stent Graft Distal Diameter
- 135cm Catheter Working Length
- 6F Delivery System Outer Profile
- 200mm Covered Stent Graft Length
TSG-6.0X200
- Central/peripheral venous endovascular stent-graft